0001572426-17-000028.txt : 20170802
0001572426-17-000028.hdr.sgml : 20170802
20170802213245
ACCESSION NUMBER: 0001572426-17-000028
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170731
FILED AS OF DATE: 20170802
DATE AS OF CHANGE: 20170802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HORN JURGEN
CENTRAL INDEX KEY: 0001652810
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36828
FILM NUMBER: 171001910
MAIL ADDRESS:
STREET 1: C/O NEXVET BIOPHARMA PLC
STREET 2: NIBRT, FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK, CO. DUBLIN
STATE: L2
ZIP: L2
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nexvet Biopharma plc
CENTRAL INDEX KEY: 0001618561
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
BUSINESS PHONE: 353 1 215 8100
MAIL ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
FORMER COMPANY:
FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd
DATE OF NAME CHANGE: 20140903
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2017-07-31
1
0001618561
Nexvet Biopharma plc
NVET
0001652810
HORN JURGEN
C/O NEXVET BIOPHARMA PLC
UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD
TULLAMORE
L2
R35 FR98
IRELAND
0
1
0
0
Chief Product Development Ofcr
Ordinary Shares
2017-07-31
4
D
0
15750
6.72
D
0
D
Option to purchase Ordinary Shares
5.10
2017-07-31
4
D
0
60000
1.62
D
2022-08-26
Ordinary Shares
60000
0
D
Restricted Share Units
.125
2017-07-31
4
D
0
47250
6.595
D
2021-07-01
Ordinary Shares
47250
0
D
Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer (the "Acquisition")
This option to purchase Ordinary Shares, which would have vested as to 12,000 shares on each of 9/30/17, 12/31/17, 3/31/18, 6/30/18, 9/30/18, 12/31/18, 3/31/19 and 6/30/19, was cancelled in the Acquisition in exchange for a cash payment equal to $97,200. This amount represents the difference between such exercise price per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on exercise of the option.
This restricted share unit, which would have vested and become convertible as to 15,750 shares on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share of $0.125 to the Issuer within 30 days of vesting, was cancelled in the Acquisition in exchange for a cash payment equal to $311,613.75. This amount represents the difference between such nominal value per share and the $6.72 consideration per share payable in connection with in the Acquisition, multiplied by the number of shares issuable on conversion of the restricted share unit.
/s/ Jurgen Horn by Geraldine T. Farrell, Attorney-in-Fact
2017-07-31